Overview

Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone

Status:
Unknown status

Trial end date:
2005-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, tolerability and safety of patients on long-acting Risperidone microshpheres injection. The major advantage of long-acting injection over oral medication is facilitation of compliance in medication taking. Non-compliance is very common among schizophrenic and is a frequent cause of relapse.

Phase:

N/A

Details

Lead Sponsor:

Hospital Authority, Hong Kong

Collaborator:

Janssen Pharmaceutica N.V., Belgium

Treatments:

Antipsychotic Agents
Risperidone